First Horizon Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $34.4K | Hold |
1,090
| – | – | ﹤0.01% | 1197 |
|
|
2025
Q1 | $35.7K | Hold |
1,090
| – | – | ﹤0.01% | 1082 |
|
|
2024
Q4 | $39.4K | Hold |
1,090
| – | – | ﹤0.01% | 1050 |
|
|
2024
Q3 | $34K | Hold |
1,090
| – | – | ﹤0.01% | 1164 |
|
|
2024
Q2 | $29.2K | Sell |
1,090
-113
| -9% | -$3.27K | ﹤0.01% | 1140 |
|
|
2024
Q1 | $41K | Hold |
1,203
| – | – | ﹤0.01% | 1047 |
|
|
2023
Q4 | $34.8K | Sell |
1,203
-211
| -15% | -$5.59K | ﹤0.01% | 1105 |
|
|
2023
Q3 | $39K | Hold |
1,414
| – | – | ﹤0.01% | 959 |
|
|
2023
Q2 | $42.5K | Buy |
1,414
+211
| +18% | +$7.38K | ﹤0.01% | 952 |
|
|
2023
Q1 | $43.6K | Hold |
1,203
| – | – | ﹤0.01% | 936 |
|
|
2022
Q4 | $42.9K | Hold |
1,203
| – | – | ﹤0.01% | 917 |
|
|
2022
Q3 | $40K | Hold |
1,203
| – | – | ﹤0.01% | 926 |
|
|
2022
Q2 | $34K | Buy |
+1,203
| New | +$34.5K | ﹤0.01% | 1088 |
|
|
2022
Q1 | – | Sell |
-1,486
| Closed | -$43K | – | 2252 |
|
|
2021
Q4 | $43K | Buy |
1,486
+283
| +24% | +$8.59K | ﹤0.01% | 979 |
|
|
2021
Q3 | $32K | Hold |
1,203
| – | – | ﹤0.01% | 1095 |
|
|
2021
Q2 | $37K | Sell |
1,203
-130
| -10% | -$3.98K | ﹤0.01% | 892 |
|
|
2021
Q1 | $34K | Buy |
1,333
+685
| +106% | +$19.2K | ﹤0.01% | 882 |
|
|
2020
Q4 | $16K | Buy |
648
+224
| +53% | +$4.82K | ﹤0.01% | 959 |
|
|
2020
Q3 | $8K | Hold |
424
| – | – | ﹤0.01% | 1073 |
|
|
2020
Q2 | $10K | Buy |
+424
| New | +$9.37K | ﹤0.01% | 1013 |
|
|
2019
Q3 | – | Sell |
-554
| Closed | -$18K | – | 1631 |
|
|
2019
Q2 | $18K | Hold |
554
| – | – | ﹤0.01% | 904 |
|
|
2019
Q1 | $19K | Hold |
554
| – | – | ﹤0.01% | 861 |
|
|
2018
Q4 | $18K | Hold |
554
| – | – | ﹤0.01% | 837 |
|
|
2018
Q3 | $27K | Hold |
554
| – | – | ﹤0.01% | 778 |
|
|
2018
Q2 | $32K | Hold |
554
| – | – | ﹤0.01% | 727 |
|
|
2018
Q1 | $24K | Hold |
554
| – | – | ﹤0.01% | 741 |
|
|
2017
Q4 | $23K | Hold |
554
| – | – | ﹤0.01% | 788 |
|
|
2017
Q3 | $22K | Hold |
554
| – | – | ﹤0.01% | 770 |
|
|
2017
Q2 | $22K | Hold |
554
| – | – | ﹤0.01% | 749 |
|
|
2017
Q1 | $18K | Hold |
554
| – | – | ﹤0.01% | 852 |
|
|
2016
Q4 | $10K | Hold |
554
| – | – | ﹤0.01% | 1003 |
|
|
2016
Q3 | $10K | Hold |
554
| – | – | ﹤0.01% | 995 |
|
|
2016
Q2 | $10K | Hold |
554
| – | – | ﹤0.01% | 964 |
|
|
2016
Q1 | $8K | Hold |
554
| – | – | ﹤0.01% | 1051 |
|
|
2015
Q4 | $7K | Sell |
554
-258
| -32% | -$3.99K | ﹤0.01% | 995 |
|
|
2015
Q3 | $11K | Hold |
812
| – | – | ﹤0.01% | 964 |
|
|
2015
Q2 | $13K | Buy |
+812
| New | +$11.6K | ﹤0.01% | 957 |
|
Other funds holding SUPN
AC
SIMG
First Horizon Advisors's SUPN Position: Q2 2025 in Review
First Horizon Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2025 at 1,090 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1197.
First Horizon Advisors first reported a position in SUPN in Q2 2015 and has held it in 37 quarters since. The position peaked at $43.6K in Q1 2023. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.
- First Horizon Advisors held 1,090 shares of Supernus Pharmaceuticals worth $34.4K as of Q2 2025.
- First Horizon Advisors left its Supernus Pharmaceuticals share count unchanged in Q2 2025.
- Supernus Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1197 holding.
- First Horizon Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
- First Horizon Advisors's Supernus Pharmaceuticals position peaked at $43.6K in Q1 2023.
- 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.